Search

Coloplast A-S (Class B)

Fermé

491.1 1.82

Résumé

Variation du prix de l'action

24h

Actuel

Min

476.1

Max

491.6

Chiffres clés

By Trading Economics

Revenu

70M

875M

Ventes

2M

7B

P/E

Moyenne du Secteur

32.582

84.243

BPA

3.88

Rendement du dividende

4.29

Marge bénéficiaire

12.572

Employés

16,744

EBITDA

2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.29%

2.28%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4B

119B

Ouverture précédente

489.28

Clôture précédente

491.1

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 févr. 2026, 23:26 UTC

Principaux Mouvements du Marché

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 févr. 2026, 22:31 UTC

Résultats

Correction to America Movil 4Q Profit Article

10 févr. 2026, 22:22 UTC

Résultats

America Movil 4Q Profit Jumps on Lower Financial Costs

10 févr. 2026, 23:51 UTC

Market Talk
Résultats

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 févr. 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 févr. 2026, 23:40 UTC

Market Talk
Résultats

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 févr. 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 févr. 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10 févr. 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 févr. 2026, 22:15 UTC

Résultats

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 févr. 2026, 22:10 UTC

Résultats

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 févr. 2026, 22:10 UTC

Résultats

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 févr. 2026, 22:09 UTC

Résultats

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 févr. 2026, 22:09 UTC

Résultats

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 févr. 2026, 22:01 UTC

Résultats

Intact Financial 4Q EPS C$5.24 >IFC.T

10 févr. 2026, 21:54 UTC

Résultats

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 févr. 2026, 21:53 UTC

Résultats

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 févr. 2026, 21:51 UTC

Résultats

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 févr. 2026, 21:51 UTC

Résultats

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 févr. 2026, 21:51 UTC

Résultats

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 févr. 2026, 21:51 UTC

Résultats

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 févr. 2026, 21:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 févr. 2026, 21:50 UTC

Résultats
Acquisitions, Fusions, Rachats

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 févr. 2026, 21:50 UTC

Résultats

James Hardie Industries 3Q EPS 12c >JHX

10 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 févr. 2026, 21:50 UTC

Résultats

James Hardie Industries 3Q Adj EPS 24c >JHX

10 févr. 2026, 21:49 UTC

Résultats

James Hardie Industries 3Q Sales $1.24B >JHX

10 févr. 2026, 21:49 UTC

Résultats
Acquisitions, Fusions, Rachats

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 févr. 2026, 21:48 UTC

Résultats
Acquisitions, Fusions, Rachats

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 févr. 2026, 21:47 UTC

Résultats
Acquisitions, Fusions, Rachats

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat